TIM-3 Qualifies as a Potential Immunotherapeutic Target in Specific Subsets of Patients with High-Risk Soft Tissue Sarcomas (HR-STS). - Berclaz, Luc M.; Altendorf-Hofmann, Annelore; Lindner, Lars H.; Burkhard-Meier, Anton; Di Gioia, Dorit; Dürr, Hans Roland; Klein, Alexander; Albertsmeier, Markus; Schmidt-Hegemann, Nina-Sophie; Klauschen, Frederick; Knösel, Thomas (Cancers, 2023)